Revance Therapeutics, Inc.
(NASDAQ : RVNC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. -2.93%46.110.0%$300.23m
VRXValeant Pharmaceuticals International, Inc. 0.77%28.7014.1%$168.87m
HZNPHorizon Therapeutics Plc 0.59%113.555.5%$127.41m
ICLRICON plc -0.20%277.032.8%$116.56m
CTLTCatalent, Inc. -1.25%131.562.0%$100.14m
JAZZJazz Pharmaceuticals Plc 1.11%145.602.1%$95.72m
PRGOPerrigo Co. Plc 0.31%45.796.9%$75.70m
UTHRUnited Therapeutics Corp. 3.15%192.2314.0%$66.43m
ARGXargenx SE 0.47%296.970.0%$53.28m
BHCBausch Health Cos., Inc. 0.76%28.700.0%$43.53m
AXSMAxsome Therapeutics, Inc. 4.48%41.981.8%$42.07m
GRVIGrove, Inc. -16.22%6.400.0%$39.16m
PCRXPacira Biosciences, Inc. 1.11%53.119.8%$32.08m
ENDPEndo International Plc 1.07%4.268.5%$31.64m
RVNCRevance Therapeutics, Inc. 13.94%15.786.1%$28.10m

Company Profile

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.